Cancer
Breast cancer in Chengdu
成都 乳腺癌
5 hospitals in Chengdu
Order: papers led on breast cancer, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for breast cancer: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Chengdu may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 313 papers led
- 56 papers led
- 31 papers ledNo open trial led
- 21 papers ledNo open trial led
- 20 papers ledNo open trial led
Breast cancer in every city Chengdu on the disease page, with the national map
open trials on breast cancer with a hospital in Chengdu
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Chengdu as lead sponsor or study site. 11 of them are led by a hospital in Chengdu. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingA Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07347600
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Weifang, Wuhan, Xi'an, Xiamen, Yangzhou, Zhengzhou
- RecruitingA Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07389733
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Dalian
- RecruitingRO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
- Phase
- Phase 2/Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07413939
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shantou, Tianjin, Urumqi, Wuhan
- RecruitingBGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
- Phase
- Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07492641
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Kunming, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2026-04
- Posted
- Registry
- NCT07518173
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Guangzhou
- RecruitingEfficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07581834
Age 18 years to Not stated; women only (registered criteria)
Led by Fujian Cancer Hospital; 1 listed hospital as study siteChengdu, Fuzhou
- RecruitingClinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects
- Phase
- Phase 1/Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07697443
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chengdu, Guangzhou, Meizhou, Tianjin, Wuhan
- RecruitingSMP-656 for HER2-Positive Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07726342
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Shenyang, Shijiazhuang, Wuhan, Xi'an, Zhengzhou
- RecruitingA Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07876557
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Jinan, Lanzhou, Nanchang, Nanjing, Qingdao, Shenyang, Shijiazhuang, Taiyuan, Weifang, Wuhan, Yinchuan, Zhengzhou
- RecruitingA Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT06790693
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Kunming, Nanning, Tianjin, Urumqi, Xi'an, Xiangyang
- RecruitingA Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06827236
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBengbu, Changchun, Chengdu, Chongqing, Nanning, Shanghai, Xi'an
- RecruitingA Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06841354
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanjing, Nanning, Taiyuan, Taizhou, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou
- RecruitingA Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06891833
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesAnyang, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Luoyang, Nanchang, Nanning, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou
- RecruitingA Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Phase
- Phase 2/Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT06926868
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesAnyang, Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanning, Qingdao, Shenyang, Taiyuan, Tianjin, Wuhan, Xiangyang, Zhengzhou
- RecruitingThe Application of "HUAXI Hole 1" in Reverse-sequence Endoscopic Nipple-sparing Mastectomy With Direct-to-implant Breast Reconstruction
- Phase
- N/A
- Started
- 2025-06
- Posted
- Registry
- NCT06995118
Age 18 years to 70 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesChangchun, Chengdu, Fuzhou, Guangzhou, Nanchang, Zhengzhou
- RecruitingA Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07043725
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 52 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Harbin, Hefei, Hengyang, Jinan, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Xinxiang, Yantai, Zhengzhou
- RecruitingTQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07047365
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 44 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guiyang, Haikou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Luzhou, Nanchang, Nanchong, Nanjing, Nanning, Ningbo, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Tangshan, Tianjin, Weifang, Wenzhou, Xi'an, Xiangyang, Xining, Xinxiang, Xuzhou, Zhengzhou
- RecruitingA Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07060807
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Taizhou, Urumqi, Xi'an, Xiamen, Xiangyang, Zhengzhou
- RecruitingA Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07169994
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesAnyang, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Luoyang, Meizhou, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Xiangyang
- RecruitingA Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07174336
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Harbin, Shanghai, Shantou, Tianjin, Wuhan
- RecruitingA Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2025-12
- Posted
- Registry
- NCT07274852
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu
- RecruitingA Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT07673029
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 51 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Meizhou, Nanchang, Nanning, Qingdao, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xi'an, Xinxiang, Xuzhou, Yantai, Zhengzhou
- RecruitingA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Phase
- Phase 2
- Started
- 2024-02
- Posted
- Registry
- NCT06172478
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Guangzhou
- RecruitingA Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
- Phase
- Not given
- Started
- 2024-01
- Posted
- Registry
- NCT06210776
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Kunming, Luoyang, Nanchang, Nanjing, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Taiyuan, Tangshan, Tianjin, Urumqi, Weifang, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou, Zhuhai
- RecruitingSBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC
- Phase
- Phase 3
- Started
- 2024-11
- Posted
- Registry
- NCT06627712
Age 18 years to 65 years; women only (registered criteria)
Led by West China HospitalChengdu
- RecruitingNeoadjuvant Chemoradiotherapy Compared to Neoadjuvant Chemotherapy for Luminal-Type Locally Advanced Breast Cancer: A Clinical Study
- Phase
- N/A
- Started
- 2024-11
- Posted
- Registry
- NCT06697938
Age 18 years to 70 years (registered criteria)
Led by Sichuan Cancer HospitalChengdu
- RecruitingA Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2024-07
- Posted
- Registry
- NCT07923214
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChengdu, Fuzhou, Shanghai
- RecruitingA Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
- Phase
- Phase 3
- Started
- 2023-06
- Posted
- Registry
- NCT05646862
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Tianjin, Wuhan
- RecruitingEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Phase
- Phase 3
- Started
- 2023-10
- Posted
- Registry
- NCT05696626
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 57 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Kunming, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou
- RecruitingEfficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
- Phase
- Phase 3
- Started
- 2023-06
- Posted
- Registry
- NCT05891093
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer Center; 13 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nantong, Ningbo, Shanghai, Shenyang, Xi'an, Yangzhou
- RecruitingA Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2023-09
- Posted
- Registry
- NCT05894239
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Fuzhou, Hangzhou, Jinan, Luoyang, Nanchang, Nanning, Shijiazhuang, Tianjin, Wuhan
- RecruitingStudy of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
- Phase
- Phase 3
- Started
- 2023-06
- Posted
- Registry
- NCT05909332
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer Center; 13 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nantong, Ningbo, Shanghai, Shenyang, Xi'an, Yangzhou
- RecruitingA Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
- Phase
- Phase 1/Phase 2
- Started
- 2023-09
- Posted
- Registry
- NCT06064812
Age 18 years to Not stated; women only (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesChangchun, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou
- RecruitingJSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06079983
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 60 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Hengyang, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Meizhou, Nanchang, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xining, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi
- RecruitingA Study of YL202 in Selected Patients With Advanced Solid Tumors
- Phase
- Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06107686
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jinan, Meizhou, Nanchang, Nanning, Qingdao, Shanghai, Shantou, Shenyang, Suzhou, Taiyuan, Taizhou, Urumqi, Weifang, Wuhan, Xi'an, Xiangyang, Xuzhou, Zhengzhou
- RecruitingStudy of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
- Phase
- Phase 2
- Started
- 2022-11
- Posted
- Registry
- NCT05447702
Age 18 years to 75 years; women only (registered criteria)
Led by West China HospitalChengdu
- RecruitingRinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Phase
- Phase 1/Phase 2
- Started
- 2022-12
- Posted
- Registry
- NCT05579366
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan
- RecruitingA Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2022-01
- Posted
- Registry
- NCT05851014
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an, Yinchuan, Zhengzhou
- Not yet recruitingCellular-Level Fluorescence Imaging for Intraoperative Margin Assessment in Breast Cancer
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07311317
Age 18 years to 70 years; women only (registered criteria)
Led by West China Hospital; 1 listed hospital as study siteChengdu
- Not yet recruitingThe Comparison Between M-E-BCS and C-O-BCS.
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07539545
Age 18 years to 70 years; women only (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingA Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07560124
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Chengdu, Harbin
- Not yet recruitingThe Comparison Between DEDTI BR and T/E BR
- Phase
- Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07593846
Age 18 years to 70 years; women only (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingCulmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07745257
Age 18 years to 80 years; women only (registered criteria)
Led by Sun Yat-sen University Cancer Center; 8 listed hospitals as study sitesAnyang, Chengdu, Dalian, Guangzhou, Hangzhou, Nanchang, Nanjing, Shijiazhuang, Zhengzhou
- Not yet recruitingA Comparative Study of Delayed Endoscopic DTI and Latissimus Dorsi ±Impalnt Reconstruction Post-Mastectomy
- Phase
- Not given
- Started
- 2026-09
- Posted
- Registry
- NCT07757074
Age 18 years to 70 years; women only (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingA Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast Cancer
- Phase
- N/A
- Started
- 2026-09
- Posted
- Registry
- NCT07782086
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Chengdu, Hefei, Luzhou, Nanjing, Shanghai, Xi'an, Xuzhou
- Not yet recruitingDrain Removal on Postoperative Safety and Patient Satisfaction in R-E-NSM With Prepectoral DIBR
- Phase
- N/A
- Started
- 2025-12
- Posted
- Registry
- NCT07237828
Age 18 years to 70 years; women only (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingA Nationwide Multicenter, Single-arm, Retrospective Study of Delayed Endoscopic DTI-BR After Simple Mastectomy
- Phase
- N/A
- Started
- 2025-12
- Posted
- Registry
- NCT07257003
Age 18 years to 70 years; women only (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingStudy of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy
- Phase
- Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT05979220
Age 18 years to 75 years; women only (registered criteria)
Led by West China HospitalChengdu
- Enrolling by invitationInfluencing Factors and Mechanisms of Capsular Contracture After Prosthesis Reconstruction in Patients With Breast Cancer
- Phase
- Not given
- Started
- 2026-03
- Posted
- Registry
- NCT07419971
Age 18 years to 80 years; women only (registered criteria)
Led by West China HospitalChengdu
- Enrolling by invitationA Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07376629
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesAnyang, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanjing, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Chengdu
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Lung cancer | Pancreatic cancer | Breast cancer | Glioma | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Lymphoma | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Coronary heart disease | Congenital heart disease | Scoliosis | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Affiliated Hospital of Chengdu University成都大学附属医院 | 7 | none | 30 | 14 | 41 | none | 20 | none | none | none | 1 | 5 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 8 | none | none | none | none | none | 8 | none | 3 | none | none | none | none | 2 | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | |
| Affiliated Hospital of Southwest Jiaotong University成都市第三人民医院 | none | none | none | none | none | none | none | none | none | none | 1 | 0 | 5 | none | none | none | none | none | none | none | 1 | 2 | none | none | none | none | none | none | none | none | none | 7 | none | 4 | none | none | 0 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Affiliated Sport Hospital of Chengdu Sport University成都体育学院附属体育医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Affiliated Women's and Children's Hospital of Chengdu Medical College四川省妇幼保健院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 4 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Chengdu Eighth People's Hospital成都市第八人民医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Chengdu Fifth People's Hospital成都市第五人民医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Chengdu First People's Hospital成都市中西医结合医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Chengdu Jinniu District People's Hospital成都市金牛区人民医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Chengdu Qingbaijiang District People's Hospital成都市青白江区人民医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Chengdu Second People's Hospital成都市第二人民医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Chengdu Seventh People's Hospital成都市第七人民医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Child Health Hospital | none | none | none | none | 01 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Children's Central Hospital, University of Electronic Science成都市妇女儿童中心医院 | none | none | none | none | none | none | none | none | 2 | none | none | none | none | 1 | none | none | none | none | none | none | 0 | 1 | none | none | none | none | none | none | none | none | none | none | 10 | none | 2 | none | none | 1 | none | 1 | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital of Chengdu Medical College成都医学院第一附属医院 | none | none | 8 | 6 | none | 2 | none | none | none | 2 | none | 1 | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | 4 | none | none | none | none | none | none | 1 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Fourth Hospital of Sichuan University四川大学华西第四医院 | none | none | none | none | none | none | 21 | none | none | none | none | 0 | none | 1 | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | 5 | none | none | none | none | none | none | none | 1 | none | 2 | none | none | none | 1 | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Gastrointestinal Cancer Centre华西-牛津消化道肿瘤研究中心 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | |
| People's Liberation Army The General Hospital中国人民解放军西部战区总医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Sciences Sichuan Translational Medicine Research Hospital中国科学院四川转化医学研究医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Second Affiliated Hospital of Chengdu Medical College成都医学院第二附属医院(核工业四一六医院) | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Sichuan Cancer Hospital四川省肿瘤医院 | 252 open | 501 open | 191 open | 13 | 1117 open | 5 | 561 open | none | none | none | none | 0 | 3 | 1 | none | none | none | none | none | 17 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Sichuan Provincial People's Hospital四川省人民医院 | 3 | 5 | 42 | 24 | 53 | 16 | 31 | 25 | none | none | 1 | 6 | 3 | 2 | none | 13 | none | none | none | 9 | none | 0 | 1 | none | none | 7 | none | 2 | none | none | none | 15 | 5 | none | 2 | 0 | 10 | 17 | none | 5 | none | none | none | none | 1 | 1 | 101 open | none | none | none | 0 | 1 | 1 | none | none | 1 | 1 | none | none | none | none | |
| Sichuan Taikang Hospital四川泰康医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| West China Hospital四川大学华西医院 | 442 open | 716 open | 39216 open | 1684 open | 68224 open | 1639 open | 31310 open | 1691 open | 4 | 1 | 3 | 36 | 33 | 52 open | 9 | 59 | 1 | 4 | 12 | 1451 open | 2 | 4 | none | 2 | 1 | 36 | 11 | 16 | 11 | none | 7 | 872 open | 127 | 371 open | 22 | 3 | 14 | 31 | 2 | 60 | 1 | 5 | 2 | 2 | 6 | 2 | 34 | 0 | none | 0 | 11 | 3 | 5 | 1 | 4 | 2 | 0 | none | none | none | none | |
| West China Hospital of Stomatology四川大学华西口腔医院 | 1 | none | none | none | none | none | none | none | none | none | none | 5 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| West China Second University Hospital四川大学华西第二医院 | none | none | none | none | none | none | none | 9 | 1 | none | none | 1 | 1 | 3 | 1 | none | 2 | 3 | 7 | 4 | 2 | 1 | none | none | none | none | none | 0 | none | none | 4 | 15 | 52 | 2 | 5 | 1 | none | 2 | 1 | 1 | 2 | 0 | 0 | 21 | 0 | 1 | 1 | none | none | 2 | none | none | 3 | 1 | none | none | none | none | none | none | none | |
| Xindu District People's Hospital成都市新都区人民医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Chengdu.
- Nasopharyngeal carcinoma 3
- Oesophageal squamous cell carcinoma 5
- Hepatocellular carcinoma 42
- Stomach cancer 24
- Lung cancer 53
- Pancreatic cancer 16
- Breast cancer 31
- Glioma 25
- Chordoma 1
- Osteosarcoma 6
- Gastrointestinal stromal tumour 3
- Neuroblastoma 2
- Multiple myeloma 13
- Lymphoma 9
- Haemophilia A 0
- Atypical haemolytic uraemic syndrome 1
- Neuromyelitis optica spectrum disorder 7
- Myasthenia gravis 2
- Coronary heart disease 15
- Congenital heart disease 5
- Anti-NMDA receptor encephalitis 2
- Takayasu arteritis 0
- Hepatic echinococcosis 10
- Idiopathic pulmonary fibrosis 17
- Amyotrophic lateral sclerosis 5
- Behçet disease 1
- Alport syndrome 1
- IgA nephropathy 101 open
- Primary biliary cholangitis 0
- Primary sclerosing cholangitis 1
- Congenital diaphragmatic hernia 1
- Hereditary angioedema 1
- Familial adenomatous polyposis 1
- Nasopharyngeal carcinoma 442 open
- Oesophageal squamous cell carcinoma 716 open
- Hepatocellular carcinoma 39216 open
- Stomach cancer 1684 open
- Lung cancer 68224 open
- Pancreatic cancer 1639 open
- Breast cancer 31310 open
- Glioma 1691 open
- Hepatoblastoma 4
- Retinoblastoma 1
- Chordoma 3
- Osteosarcoma 36
- Gastrointestinal stromal tumour 33
- Neuroblastoma 52 open
- Ewing sarcoma 9
- Multiple myeloma 59
- B-cell acute lymphoblastic leukaemia 1
- Aplastic anaemia 4
- Haemophagocytic lymphohistiocytosis 12
- Lymphoma 1451 open
- Beta thalassaemia 2
- Haemophilia A 4
- Thrombotic thrombocytopenic purpura 2
- Fanconi anaemia 1
- Neuromyelitis optica spectrum disorder 36
- IgG4-related disease 11
- Myasthenia gravis 16
- Moyamoya disease 11
- Biliary atresia 7
- Coronary heart disease 872 open
- Congenital heart disease 127
- Scoliosis 371 open
- Anti-NMDA receptor encephalitis 22
- Takayasu arteritis 3
- Hepatic echinococcosis 14
- Idiopathic pulmonary fibrosis 31
- Lymphangioleiomyomatosis 2
- Amyotrophic lateral sclerosis 60
- Spinal muscular atrophy 1
- Fabry disease 5
- Pompe disease 2
- Duchenne muscular dystrophy 2
- Behçet disease 6
- Alport syndrome 2
- IgA nephropathy 34
- Gaucher disease 0
- Osteogenesis imperfecta 0
- Primary biliary cholangitis 11
- Primary sclerosing cholangitis 3
- Congenital diaphragmatic hernia 5
- Hirschsprung disease 1
- Inherited epidermolysis bullosa 4
- Hereditary angioedema 2
- Familial adenomatous polyposis 0
- Glioma 9
- Hepatoblastoma 1
- Osteosarcoma 1
- Gastrointestinal stromal tumour 1
- Neuroblastoma 3
- Ewing sarcoma 1
- B-cell acute lymphoblastic leukaemia 2
- Aplastic anaemia 3
- Haemophagocytic lymphohistiocytosis 7
- Lymphoma 4
- Beta thalassaemia 2
- Haemophilia A 1
- Myasthenia gravis 0
- Biliary atresia 4
- Coronary heart disease 15
- Congenital heart disease 52
- Scoliosis 2
- Anti-NMDA receptor encephalitis 5
- Takayasu arteritis 1
- Idiopathic pulmonary fibrosis 2
- Lymphangioleiomyomatosis 1
- Amyotrophic lateral sclerosis 1
- Spinal muscular atrophy 2
- Fabry disease 0
- Pompe disease 0
- Duchenne muscular dystrophy 21
- Behçet disease 0
- Alport syndrome 1
- IgA nephropathy 1
- Osteogenesis imperfecta 2
- Congenital diaphragmatic hernia 3
- Hirschsprung disease 1
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for breast cancer.
Counts are listed hospitals only, not every hospital in each city.
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Chengdu on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.